Schott unveils new adaptiQ system solution for ready-to-use pharmaceutical vials that consists of a nest and tub configuration that can hold up to 100 vials, allows for immediate filling without processing steps like washing, drying and sterilization

Elyse Blye

Elyse Blye

MAINZ, Germany , October 24, 2013 (press release) – Patented design allows for lyophilization and closing of pharmaceutical vials in the nest

With adaptiQ, SCHOTT will be unveiling a new concept of ready-to-use pharmaceutical vials that has been modified in close cooperation with filling line manufacturers to meet the process requirements of the pharmaceutical industry. SCHOTT adaptiQ consists of a nest and tub configuration that allows for as many as 100 vials to be securely fixed inside a holder (nest) and delivered to the pharmaceutical company packaged in a sterile container. The company can then fill these vials on its filling line immediately without having to perform arduous processing steps like washing, drying and sterilization. What makes SCHOTT’s innovation unique is its patented nest design; unlike all of the other solutions currently on the market, adaptiQ allows for vials to be subjected to all of the processing steps while inside the nest, even freeze-drying, weighing and closing for the first time ever. Besides simplifying the process, the main focus is on protecting the glass containers, which can no longer come into contact with each other or be scratched by coming into contact with machine components. Market introduction is scheduled for Q3/2014 and will start with the most popular ISO formats 2R and 4R. SCHOTT adaptiQ is expected to be gradually introduced in all of the most common ISO formats ranging from 2 to 30 ml. The company plans to make initial samples available starting at the end of October 2013.

Companies are showing much greater interest in flexible manufacturing concepts that allow for small batches or different ingredients/packaging configurations to be filled more efficiently. SCHOTT adaptiQ responds to this challenge by offering three special advantages, as Product Manager Gregor Deutschle explains: “If pharmaceutical companies can use the same production line for various lot sizes and different types of containers like syringes, vials and cartridges, this gives them much greater freedom to react to new market demands more quickly. Moreover, costs can be lowered by shortening the process chain and reducing its complexity. It is then no longer necessary to invest in clean rooms, special washing machines and sterilization tunnels, or spend money to operate them.”

Yet another advantage is the avoided glass-to-glass contact: securely fixed inside the nest, the containers are no longer able to tip over, fall out or collide with one another. This not only reduces the reject rate, but ensures the cosmetic quality of these packaging products.

Patented nest design
Pharmaceutical companies have already been benefiting from these advantages in other areas of packaging for years now. Roughly 80 percent of all pre-filled syringes that are sold in the world today are delivered to the filling lines in the form of a nest and tub configuration. Attempts to apply this successful syringe approach to other types of containers have failed in the past because vials still had to be individually removed from the nest for certain processing steps.

The patented, new nest design that adaptiQ is based on now offers a solution to this problem for the first time ever. The vials are held by the neck and can all be lifted up or out of the nest together. Furthermore, the bottom is freely accessible and thus ensures the perfect temperature transition, especially during lyophilization. Here, the patented design developed by SCHOTT follows the common format of syringe manufacturing to ensure that adaptiQ can also be processed on existing nest filling lines.

Premiere at the trade exhibition CPhI
Visitors to booth 41D21 will have the chance to see adaptiQ vials for the first time from October 22 – 24, 2013. In addition, Product Manager Gregor Deutschle will be presenting SCHOTT adaptiQ as part of the CPhI Speakers’ Corner (10/23, 10:30 – 10:55 AM).

About SCHOTT

SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glasses and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, solar power, pharmaceuticals, electronics, optics, transportation and architecture industries. The company is strongly committed to contributing to its customers’ success and making SCHOTT an important part of people’s lives with high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in 35 countries. Its workforce of around 16,000 employees generated worldwide sales of approximately 2 billion euros for the 2011/2012 fiscal year. SCHOTT AG, with its headquarters in Mainz (Germany) is owned by the Carl Zeiss Foundation.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

Share:

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.